The Food and Drug Administration (FDA) conducted an inspection of Newark Beth Israel Medical Center – Blood Bank in Newark on April 22, evaluating blood and blood product procedures, according to data posted on the FDA’s website.
The concluding report stated no corrective actions were necessary for Newark Beth Israel Medical Center – Blood Bank’s operational management.
The FDA regularly inspects facilities throughout the country to ensure both workplaces and products adhere to FDA-enforced laws and regulations designed to protect public health. These inspection results are available to the public.
According to its website, the FDA is a federal agency primarily tasked with overseeing the safety and quality of human and veterinary drugs, biological products, medical devices, and tobacco products.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
